Specialist Supplements COL-Clear B Internal Cleanse Support 100 Capsules

Product Information

Across both treatment groups, of the six patients with HBsAg reductions >3.0 log 10 IU/ml, four patients had levels falling below the limit of quantification (0.05 IU/ml). Prolonged HBsAg loss was observed in one-NA treated patient (from Day 36 to Day 113) and one NA-naïve patient (from Day 23 to Day 126). Chris Corsico, SVP, Development, GSK, said: “Today’s results from the B-Clear study are a promising step forward for the approximately 300 million people living with chronic hepatitis B. We look forward to confirming these findings for bepirovirsen in our phase III study starting next year, as well as exploring potential sequential therapy options with the aim of helping more people living with CHB achieve functional cure.” Hepatitis B is a viral infection, caused by the hepatitis B virus (HBV), in the liver that can cause both acute and chronic liver disease. [2] Chronic hepatitis B (CHB) is a long-lasting infection and occurs when the body’s immune system is unable to fight off the virus and it persists in the blood and liver. [3] It is estimated that there are 257 million people globally with CHB. [3] Even when treated, CHB can progress to liver failure and liver cancer, which results in nearly 900,000 deaths per year. [4] Around 22 million people get diagnosed and of these only 1.7 million (8%) get treated. [3]

There is a need for therapeutic approaches that enable not only suppression of viral replication, but resolution of chronic HBV infection. About GSK3228836 Hepatitis B Fact sheet. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.Updated on July 18, 2019. Accessed on November 29, 2019

External scientific engagement on the start of the phase IIb study of GSK4532990 in adults with nonalcoholic steatohepatitis (NASH).

For the selected 300mg dose of GSK’836, reductions in HBsAg were observed in NA-treated (HBeAg negative) and NA-naïve patients (HBeAg positive and negative): Chris Stevens holds a BA in chemistry from the University of North Carolina at Chapel Hill, an M.D. degree from the University of Miami in Florida, and attended management classes at the Harvard extension school. He has been an invited speaker to graduating gastroenterology fellows and the Harvard translational medicine course regarding careers in the biopharmaceutical industry. He has over 20 years of biopharmaceutical drug development experience.Phase 2a data to be presented at The Digital International Liver Congress suggests potential of investigational drug (GSK3228836) to suppress hepatitis B virus after four weeks of treatment.

Phase II trial of bepirovirsen in sequential combination with GSK’s chronic hepatitis B targeted immunotherapy. UK based test Laboratories have completed the latest Gold Standard COVID-19 testing in October 2020, in which our product achieved Log4, resulting in a 99.99% virucidal kill. For more information regarding AASLD The Liver Meeting® 2021 please visit https://www.aasld.org/the-liver-meetingGSK is exploring sequential treatment trials of bepirovirsen with other therapeutic modalities, with the aim of increasing functional cure rate in more patients and reducing the overall burden of CHB. These include:

Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to specifically recognise the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) which facilitate chronicity of the disease by helping to avoid clearance by the immune system. The ASO recruits the liver’s own enzymes to eliminate the RNA by digesting it to an inactive form. The subsequent reduction in the levels of the RNA results in a decrease in both the virus and the production of viral antigen (HBsAg) by the hepatocytes, which can be measured by a drop in the HBV DNA and antigen levels in the circulating blood. Bepirovirsen has an additional property of stimulating immune responses via Toll-like receptor 8 (TLR8) which may help the immune system to achieve durable clearance of the virus from circulating blood.Viral suppression is the current goal for treatment of CHB. However, viral replicative activity may return upon cessation of treatment, requiring lifelong therapy to prevent viral rebound. The concept of functional cure of CHB aims to eliminate the virus from circulating in the blood and prevent any disease activity in the liver. As only a limited number of patients currently treated for CHB achieve HBsAg loss, considered the hallmark for achieving functional cure, development of therapeutic approaches to reach functional cure are needed. 2